Abstract
* Necitumumab (Portrazza) is a new epidermal growth factor receptor antagonist approved to treat advanced squamous non-small cell lung cancer in patients who haven't received medication for advanced lung cancer.
* Risks include cardiac arrest and hypomagnesemia. The latter is extremely common. Electrolyte levels should be monitored closely.